Jimin Kexin Pharmaceutical fined by China's SAMR for failure to notify Nanjing Hencer deal
MLex Summary: Jiangxi Jimin Kexin Pharmaceutical Industry Investment has been fined 300,000 yuan ($42,970) by China’s State Administration for Market Regulation for failing to notify its acquisition of an 83.35 percent...To view the full article, register now.
Already a subscriber? Click here to view full article